{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:23:14Z","timestamp":1793013794389,"version":"4.5.0"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Routine childhood vaccinations are key for the protection of children from a variety of serious and potentially fatal diseases. Current pediatric vaccine schedules mainly cover active vaccines. Active vaccination in infants is a highly effective approach against several infectious diseases; however, thus far, for some important viral pathogens, including respiratory syncytial virus (RSV), vaccine development and license by healthcare authorities have not been accomplished. Nirsevimab is a human-derived, highly potent monoclonal antibody (mAb) with an extended half-life for RSV prophylaxis in all infants. In this manuscript, we consider the potential implications for the introduction of an anti-viral mAb, such as nirsevimab, into the routine pediatric vaccine schedule, as well as considerations for coadministration. Specifically, we present evidence on the general mechanism of action of anti-viral mAbs and experience with palivizumab, the only approved mAb for the prevention of RSV infection in preterm infants, infants with chronic lung disease of prematurity and certain infants with hemodynamically significant heart disease. Palivizumab has been used for over two decades in infants who also receive routine vaccinations without any alerts concerning the safety and efficacy of coadministration. Immunization guidelines (Advisory Committee on Immunization Practices, Joint Committee on Vaccination and Immunization, National Advisory Committee on Immunization, Centers for Disease Control and Prevention, American Academy of Pediatrics, The Association of the Scientific Medical Societies in Germany) support coadministration of palivizumab with routine pediatric vaccines, noting that immunobiologics, such as palivizumab, do not interfere with the immune response to licensed live or inactivated active vaccines. Based on the mechanism of action of the new generation of anti-viral mAbs, such as nirsevimab, which is highly specific targeting viral antigenic sites, it is unlikely that it could interfere with the immune response to other vaccines. Taken together, we anticipate that nirsevimab could be concomitantly administered to infants with routine pediatric vaccines during the same clinic visit.<\/jats:p>","DOI":"10.3389\/fimmu.2021.708939","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T09:27:48Z","timestamp":1628674068000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper"],"prefix":"10.3389","volume":"12","author":[{"given":"Susanna","family":"Esposito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahaa","family":"Abu-Raya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabianne","family":"Cahn-Sellem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie L.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Martinon Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuncion","family":"Mejias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Nadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A. P.","family":"Safadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S0264-410X(02)00623-0","article-title":"The Global Value of Vaccination","volume":"21","author":"Ehreth","year":"2003","journal-title":"Vaccine"},{"key":"B2","unstructured":"Immunization Coverage"},{"key":"B3","unstructured":"General Best Practice Guidelines for Immunization"},{"key":"B4","unstructured":"Green Book. Chapter 1: Immunity and How Vaccines Work"},{"key":"B5","unstructured":"Vaccination Greatly Reduces Disease, Disability, Death and Inequity Worldwide"},{"key":"B6","unstructured":"Children: Improving Survival and Well-Being"},{"key":"B7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nri.2017.148","article-title":"Passive Immunotherapy of Viral Infections: \u2019Super-Antibodies\u2019 Enter the Fray","volume":"18","author":"Walker","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00542-x","article-title":"Neutralizing Monoclonal Antibodies for Treatment of COVID-19","volume":"21","author":"Taylor","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.12932\/ap-200220-0773","article-title":"Perspectives on Monoclonal Antibody Therapy as Potential Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)","volume":"38","author":"Shanmugaraj","year":"2020","journal-title":"Asian Pac J Allergy Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bsheal.2021.02.001","article-title":"An Update to Monoclonal Antibody as Therapeutic Option Against COVID-19","volume":"3","author":"Deb","year":"2021","journal-title":"Biosaf Health"},{"key":"B11","doi-asserted-by":"publisher","first-page":"ciab494","DOI":"10.1093\/cid\/ciab494","article-title":"Outpatient Treatment of SARS-CoV-2 Infection to Prevent COVID-19 Progression","author":"Cohen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B12","unstructured":"Guidance for Industry: General Principles for the Development of Vaccines to Protect Against Global Infectious Diseases"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, Regional, and National Disease Burden Estimates of Acute Lower Respiratory Infections Due to Respiratory Syncytial Virus in Young Children in 2015: A Systematic Review and Modelling Study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200207000-00005","article-title":"Respiratory Syncytial Virus-Coded Pediatric Hospitalizations, 1997 to 1999","volume":"21","author":"Leader","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/jp.2016.113","article-title":"Respiratory Syncytial Virus Hospitalization Outcomes and Costs of Full-Term and Preterm Infants","volume":"36","author":"McLaurin","year":"2016","journal-title":"J Perinatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global Burden of Acute Lower Respiratory Infections Due to Respiratory Syncytial Virus in Young Children: A Systematic Review and Meta-Analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21244","article-title":"Healthcare Costs Within a Year of Respiratory Syncytial Virus Among Medicaid Infants","volume":"45","author":"Palmer","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and Regional Mortality From 235 Causes of Death for 20 Age Groups in 1990 and 2010: A Systematic Analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13062","article-title":"Asthma and Lung Function in Adulthood After a Viral Wheezing Episode in Early Childhood","volume":"48","author":"Backman","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e017936","DOI":"10.1136\/bmjopen-2017-017936","article-title":"Association Between Respiratory Syncytial Viral Disease and the Subsequent Risk of the First Episode of Severe Asthma in Different Subgroups of High-Risk Australian Children: A Whole-of-Population-Based Cohort Study","volume":"7","author":"Homaira","year":"2017","journal-title":"BMJ Open"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1542\/pir.35-12-519","article-title":"Respiratory Syncytial Virus Infection and Bronchiolitis","volume":"35","author":"Piedimonte","year":"2014","journal-title":"Pediatr Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.01.020","article-title":"Does Respiratory Syncytial Virus Lower Respiratory Illness in Early Life Cause Recurrent Wheeze of Early Childhood and Asthma? Critical Review of the Evidence and Guidance for Future Studies From a World Health Organization-Sponsored Meeting","volume":"38","author":"Driscoll","year":"2020","journal-title":"Vaccine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz278","article-title":"Long-Term Assessment of Healthcare Utilization 5 Years After Respiratory Syncytial Virus Infection in US Infants","volume":"221","author":"Sim\u00f5es","year":"2020","journal-title":"J Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piz087","article-title":"Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2 Years in the United States, 2014-15","volume":"9","author":"Arriola","year":"2020","journal-title":"J Pediatr Infect Dis Soc"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-0303","article-title":"Respiratory Syncytial Virus-Associated Hospitalizations Among Children Less Than 24 Months of Age","volume":"132","author":"Hall","year":"2013","journal-title":"Pediatrics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e20193611","DOI":"10.1542\/peds.2019-3611","article-title":"Respiratory Syncytial Virus\u2013Associated Hospitalizations Among Young Children: 2015\u20132016","volume":"146","author":"Rha","year":"2020","journal-title":"Pediatrics"},{"key":"B27","unstructured":"RSV Symptoms and Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1177\/2049936116630243","article-title":"Best Practice in the Prevention and Management of Paediatric Respiratory Syncytial Virus Infection","volume":"3","author":"Drysdale","year":"2016","journal-title":"Ther Adv Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1155\/2002\/127953","article-title":"Polyclonal Intravenous Immunoglobulin for the Prophylaxis and Treatment of Infection in Critically Ill Adults","volume":"13","author":"Laupland","year":"2002","journal-title":"Can J Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/B978-0-323-35761-6.00008-0","article-title":"Passive Immunization","volume":"2018","author":"Slifka","year":"2018","journal-title":"Plotkin\u2019s Vaccines"},{"key":"B31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41541-017-0019-3","article-title":"Antibody Therapies for the Prevention and Treatment of Viral Infections","volume":"2","author":"Salazar","year":"2017","journal-title":"NPJ Vaccines"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01714-16","article-title":"Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody With an Extended Half-Life, in Healthy Adults","volume":"61","author":"Griffin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002312","article-title":"Why Should We Advocate Maternal Immunization","volume":"38","author":"Boonyaratanakornkit","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01282","article-title":"Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement","volume":"11","author":"Abu-Raya","year":"2020","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00108-X","article-title":"Maternal Immunization Against Viral Disease","volume":"16","author":"Englund","year":"1998","journal-title":"Vaccine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit143","article-title":"Waning of Maternal Antibodies Against Measles, Mumps, Rubella, and Varicella in Communities With Contrasting Vaccination Coverage","volume":"208","author":"Waaijenborg","year":"2013","journal-title":"J Infect Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1128\/IAI.74.4.1999-2006.2006","article-title":"Neonatal Innate Immunity to Infectious Agents","volume":"74","author":"Mar\u00f3di","year":"2006","journal-title":"Infect Immun"},{"key":"B38","unstructured":"Guidelines for Vaccinating Pregnant Women"},{"key":"B39","unstructured":"Green Book. Chapter 11: The UK Immunization Schedule"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01282","article-title":"Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement","volume":"11","author":"Abu-Raya","year":"2020","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.08.038","article-title":"The Effect of Timing of Maternal Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Immunization During Pregnancy on Newborn Pertussis Antibody Levels - A Prospective Study","volume":"32","author":"Abu Raya","year":"2014","journal-title":"Vaccine"},{"key":"B42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.eclinm.2019.06.010","article-title":"The Effect of Maternal Immunisation During Pregnancy on Infant Vaccine Responses","volume":"13","author":"Zimmermann","year":"2019","journal-title":"EClinicalMedicine"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908380","article-title":"Prepare Study Group. Respiratory Syncytial Virus Vaccination During Pregnancy and Effects in Infants","volume":"383","author":"Madhi","year":"2020","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy056","article-title":"Respiratory Syncytial Virus Seasonality: A Global Overview","volume":"217","author":"Obando-Pacheco","year":"2018","journal-title":"J Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06446-11","article-title":"Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and Children","volume":"56","author":"Robbie","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"B46","unstructured":"Synagis SmPC"},{"key":"B47","unstructured":"Synagis Prescribing Information"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab Prophylaxis Reduces Hospitalization Due to Respiratory Syncytial Virus in Young Children With Hemodynamically Significant Congenital Heart Disease","volume":"143","author":"Feltes","year":"2003","journal-title":"J Pediatr"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-Risk Infants. The IMpact-RSV Study Group","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-2862","article-title":"Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis","volume":"134","author":"Ralston","year":"2014","journal-title":"Pediatrics"},{"key":"B51","first-page":"1","article-title":"Births: Final Data for 2016","volume":"67","author":"Martin","year":"2018","journal-title":"Natl Vital Stat Rep"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.anpede.2019.08.003","article-title":"[An Update of the Recommendations of the Spanish Neonatology Society for the Use of Palivizumab as Prophylaxis for Severe Infections Due to Syncytial Respiratory Virus in High Risk Infants]","volume":"91","author":"S\u00e1nchez Luna","year":"2019","journal-title":"An Pediatr (Barc)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13052-019-0736-5","article-title":"Impact of the 2014 American Academy of Pediatrics Recommendation and of the Resulting Limited Financial Coverage by the Italian Medicines Agency for Palivizumab Prophylaxis on the RSV-Associated Hospitalizations in Preterm Infants During the 2016-2017 Epidemic Season: A Systematic Review of Seven Italian Reports","volume":"45","author":"Cutrera","year":"2019","journal-title":"Ital J Pediatr"},{"key":"B54","unstructured":"Guideline for the Prophylaxis of Serious Diseases Caused by Respiratory Syncytial Virus (RSV) in Children at Risk: Update 2017\/20182018"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001916","article-title":"Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-Life Single-Dose Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants","volume":"37","author":"Domachowske","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"B56","doi-asserted-by":"publisher","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A Highly Potent Extended Half-Life Antibody as a Potential RSV Vaccine Surrogate for All Infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci Trans Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"key":"B58","unstructured":"A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants (MELODY)"},{"key":"B59","unstructured":"A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-Risk Children"},{"key":"B60","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/00006454-199405000-00012","article-title":"Simultaneous Administration of Childhood Vaccines: An Important Public Health Policy That Is Safe and Efficacious","volume":"13","author":"King","year":"1994","journal-title":"Pediatr Infect Dis J"},{"key":"B61","unstructured":"Immunization Schedules"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.10.088","article-title":"Barriers to Vaccination in Latin America: A Systematic Literature Review","volume":"38","author":"Guzman-Holst","year":"2020","journal-title":"Vaccine"},{"key":"B63","unstructured":"Vaccination Schedules in the EU\/EEA"},{"key":"B64","unstructured":"Policy Brief: Guidelines for the Prevention, Care and Treatment of Persons With Chronic Hepatitis B Infection"},{"key":"B65","doi-asserted-by":"crossref","DOI":"10.1542\/peds.83.3.369","article-title":"Measles Outbreak Among Unvaccinated Preschool-Aged Children: Opportunities Missed by Health Care Providers to Administer Measles Vaccine","volume":"83","author":"Hutchins","year":"1989","journal-title":"Pediatrics"},{"key":"B66","unstructured":"Red Book: Simultaneous Administration of Multiple Vaccines"},{"key":"B67","unstructured":"Recommendations for Routine Immunization"},{"key":"B68","doi-asserted-by":"crossref","DOI":"10.1542\/peds.85.4.682","article-title":"Safety, Tolerability, and Immunogenicity of Concurrent Administration of Haemophilus Influenzae Type B Conjugate Vaccine (Meningococcal Protein Conjugate) With Either Measles-Mumps-Rubella Vaccine or Diphtheria-Tetanus-Pertussis and Oral Poliovirus Vaccines in 14- to 23-Month-Old Infants","volume":"85","author":"Dashefsky","year":"1990","journal-title":"Pediatrics"},{"key":"B69","doi-asserted-by":"crossref","DOI":"10.1542\/peds.81.2.237","article-title":"Simultaneous Administration of Measles-Mumps-Rubella Vaccine With Booster Doses of Diphtheria-Tetanus-Pertussis and Poliovirus Vaccines","volume":"81","author":"Deforest","year":"1988","journal-title":"Pediatrics"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6505a1","article-title":"Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2016\u201317 Influenza Season","volume":"65","author":"Grohskopf","year":"2016","journal-title":"Recomm Rep"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.042","article-title":"Febrile Seizures After 2010-2011 Influenza Vaccine in Young Children, United States: A Vaccine Safety Signal From the Vaccine Adverse Event Reporting System","volume":"30","author":"Leroy","year":"2012","journal-title":"Vaccine"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.01.027","article-title":"Signal Identification and Evaluation for Risk of Febrile Seizures in Children Following Trivalent Inactivated Influenza Vaccine in the Vaccine Safety Datalink Project, 2010-2011","volume":"30","author":"Tse","year":"2012","journal-title":"Vaccine"},{"key":"B73","article-title":"Recommendation of the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) Among Children Aged 9 Through 23 Months at Increased Risk for Invasive Meningococcal Disease","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B74","article-title":"Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged \u226565 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Tomczyk","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B75","unstructured":"Guideline on Clinical Evaluation of Vaccines2018"},{"key":"B76","unstructured":"Guideline on the Clinical Evaluation of Medicinal Products Indicated for the Prophylaxis or Treatment of Respiratory Syncytial Virus (RSV) Disease2018"},{"key":"B77","first-page":"199","volume-title":"Overview and Compartmentalization of the Immune System Hematology: Basic Principles and Practice","author":"Rao","year":"2018"},{"key":"B78","unstructured":"Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment (Guidance for Industry)2017"},{"key":"B79","unstructured":"Guidance Document: Drug-Drug Interaction Assessment for Therapeutic Proteins (Guidance for Industry)2020"},{"key":"B80","unstructured":"DohmeMS Zinplava SMPC"},{"key":"B81","unstructured":"Cosentyx SmPC"},{"key":"B82","unstructured":"Preferred Product Characteristics of Monoclonal Antibodies for Passive Immunization Against RSV2021"},{"key":"B83","unstructured":"Green Book. Chapter 6: Contraindications and Special Considerations"},{"key":"B84","unstructured":"Calendrier Des Vaccinations Et Recommandations Vaccinales2020"},{"key":"B85","unstructured":"Timing and Spacing of Immunobiologics"},{"key":"B86","article-title":"Safety Study on Simultaneous Administration of Vaccines and Palivizumab in Children","volume":"121","author":"Toishi S","year":"2017","journal-title":"J-Global"},{"key":"B87","unstructured":"Green Book. Chapter 27a: Respiratory Syncytial Virus"},{"key":"B88","unstructured":"Statement on the Recommended Use of Monoclonal Anti-RSV Antibody (Palivizumab)"},{"key":"B89","unstructured":"The Pink Book: Principles of Vaccination"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-1666","article-title":"Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection","volume":"134","year":"2014","journal-title":"Pediatrics"},{"key":"B91","doi-asserted-by":"publisher","first-page":"5278","DOI":"10.1038\/s41467-020-19096-y","article-title":"Antibodies Targeting Epitopes on the Cell-Surface Form of NS1 Protect Against Zika Virus Infection During Pregnancy","volume":"11","author":"Wessel","year":"2020","journal-title":"Nat Commun"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30470-9","article-title":"Infant Respiratory Syncytial Virus Prophylaxis and Nasopharyngeal Microbiota Until 6 Years of Life: A Subanalysis of the MAKI Randomised Controlled Trial","volume":"8","author":"Man","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix031","article-title":"Interference Between Respiratory Syncytial Virus and Human Rhinovirus Infection in Infancy","volume":"215","author":"Achten","year":"2017","journal-title":"J Infect Dis"},{"key":"B94","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.cmi.2015.10.002i","article-title":"Interference Between Respiratory Syncytial Virus and Rhinovirus in Respiratory Tract Infections in Children","volume":"22","author":"Karppinen","year":"2016","journal-title":"Clin Microbiol Infect"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.708939\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T23:04:33Z","timestamp":1673046273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.708939\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":94,"alternative-id":["10.3389\/fimmu.2021.708939"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.708939","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,11]]},"article-number":"708939"}}